Human CD20 Full-Length Proteins

CD20 is a potential target for the treatment of leukemia, lymphoma, and some autoimmune diseases. However, due to the complexity of expression and the unstable bioactivity, it is very hard to find an appropriate CD20 protein on the market for detecting the CD20-CAR expression and the bioactivity of antibody drugs.

To tackle these challenges, ACROBiosystems has designed the full-length multi-transmembrane CD20 proteins, produced by HEK293 cells and insect cells. The bioactivity and purity of the full-length CD20 protein were confirmed by ELISA, SDS-PAGE, and SPR. In addition, ACROBiosystems provides full-length CD20 protein for immunization and assessment of CD20-CAR expression.

Application

Product List

Molecule Cat. No. Host Product Description
CD20/ MS4A1 CD0-H52H3 HEK293 Human CD20/ MS4A1 Full Length Protein, His Tag
CD0-H55Ha Insect cells-HI5 Human CD20/ MS4A1 Full Length Protein, His Tag

 

Product Features

Full-length CD20 protein fully complies with both small and big loops.

Full-length CD20 protein fully complies with both small and big loops.

Full-length CD20 protein has better bioactivity.

  1. HEK293 Cell (Full Length)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL.

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–16 ng/mL.

  1. Insect Cell (Full Length)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL.

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 1–16 ng/mL.

  1. Escherichia coli (Extracellular)

Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E. coli) with a linear range of 78–2500 ng/mL.

Immobilized Rituximab at 5 μg/mL (100 μL/well) can bind Human CD20, TrxA Tag, His Tag (E. coli) with a linear range of 78–2500 ng/mL.

The bioactivity of Full-Length CD20 Protein was verified by Elisa/SPR and the protocols are presented.

ELISA

Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).

Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL.

Immobilized Ofatumumab at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with a linear range of 2–31 ng/mL.

Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind Rituximab with a linear range of 0.313–1.25 μg/mL.

Immobilized Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) at 2 μg/mL (100 μL/well) on Nickel Coated Plate, can bind Rituximab with a linear range of 0.313–1.25 μg/mL.

Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL.

Immobilized Ofatumumab (Human IgG1) at 10 μg/mL (100 μL/well) can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with a linear range of 2–31 ng/mL.

SPR

Related CD20 proteins: Cat. No. CD0-H52H3 (HEK293 expression) and Cat. No. CD0-H55Ha (Insect cells expression).

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 1.77 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, HEK293 (Cat. No. CD0-H52H3) with an affinity constant of 3.57 nM as determined in an SPR assay (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200).

MabThera® (Rituximab) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 1.21 nM as determined in an SPR assay (in presence of DDM) (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200).

Ofatumumab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Human CD20 Full Length, His Tag, Insect cell (Cat. No. CD0-H55Ha) with an affinity constant of 2.977 nM as determined in an SPR assay (Biacore T200).

About ACROBiosystems

ACROBiosystems is an internationally recognized manufacturer of recombinant proteins committed to supporting cancer immunotherapy. We specialize in mammalian cell-based recombinant protein production and process development.

Our goal is to support professionals from pharmaceutical companies, CROs and research institutes who are working on the cancer immunotherapy area by providing high-quality proteins, antibodies and assay kits.

We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Aug 14, 2019 at 4:02 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2019, August 14). Human CD20 Full-Length Proteins. News-Medical. Retrieved on October 20, 2019 from https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx.

  • MLA

    ACROBiosystems. "Human CD20 Full-Length Proteins". News-Medical. 20 October 2019. <https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx>.

  • Chicago

    ACROBiosystems. "Human CD20 Full-Length Proteins". News-Medical. https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx. (accessed October 20, 2019).

  • Harvard

    ACROBiosystems. 2019. Human CD20 Full-Length Proteins. News-Medical, viewed 20 October 2019, https://www.news-medical.net/whitepaper/20190814/Human-CD20-Full-Length-Proteins.aspx.

Other White Papers by this Supplier